"nightly love"
• on friday (22 may 2026), the a share market rebounded, with three indicators running high and the entrepreneurship board pointing and deep fingers increasing by more than 2 per cent. The value of the trade between the two cities is 2. 9 trillion, which is 57. 8 billion less than the previous date. Over 3,800 shares have risen and over 100 shares have stopped. By the time of closing, the thumbs had increased by 0. 87 per cent, to 2. 3 per cent and to 2. 84 per cent。
• on friday (22 may 2026), the hong kong equity unit experienced a three-fold shock, with a constant index exceeding 2 per cent. Up to the time of closing, the heinogeneity index had increased by 0. 86 per cent or 219. 51 points, reporting 25606. 03 points and full-time transactions at hk$ 28,298 million; the heinogeneity enterprise index by 0. 89 per cent, reporting 8550. 87 points; and the heinogeneity technology index by 21. 1 per cent, reporting 4869. 57 points. Throughout the week, the constant finger dropped by 1. 37 per cent. The country is defined as a 1. 61 per cent decline and the hexavalent index is 1. 45 per cent decline。
• on friday (22 may 2026 local time), the united states stock rose collectively, with 0. 58 per cent up to 50579. 70 points reported as a result of the roll-out, while innovation continued to increase; the standard 500 index increased by 0. 37 per cent to 7473. 47 per cent; and the net 0. 19 per cent to 26343. 97 points reported。
Today's new stock
Today, there are no shares listed and no new shares requisitioned。
"major news"
[hong kong securities commission: enhanced measures to address the risks of document forgery and money-laundering and to raise the standards for opening accounts] on 22 may, the csrh issued a circular today setting out the controls to be applied when opening accounts and maintaining customer relations. The circular was issued following an examination by the sec of the operating methods of the opening of 12 securities brokers. The inspections identified a number of significant deficiencies, including inadequate due diligence of the opening documents, the acceptance of suspicious or falsified documents in the opening of accounts and weaknesses in the management of cross-border representation with overseas intermediaries. The cvm is deeply concerned about the potential misuse of client accounts for suspicious or unlawful transactions and the resulting heightened risk of money laundering and terrorist fund raising. The cvm requires all licensees to carry out, as soon as practicable, internal verification to detect whether any suspicious or forged documents have been accepted for use in opening accounts。
On 22 may, the deputy minister of commerce and deputy representative for international trade negotiations hosted a round table of foreign companies in the pharmaceutical sector. More than 50 foreign-owned business representatives from sinofi, novartis, meshadong, bidi medical, jilind science, renaissance and dannah attended. The ministry of commerce, the ministry of industry and information technology, the national commission on health and health, the national health and safety service and the national drug authority participate and interact with enterprises in the field. The “fifty-five” period is a critical period for building a healthy china. China’s innovative ecological system for the pharmaceutical industry is complete, with the world’s largest system of health-care services, and will create great opportunities for multinational pharmaceutical companies to develop in china in the long term. The chinese government insists on a people-centred approach to improving the quality of health-care products and services on an ongoing basis, and on sound pricing and regulatory systems, expanding the scope of its openness to foreign sources in related areas and guaranteeing the national treatment of foreign-owned enterprises in accordance with the law. China's development dividend is welcomed by the fact that national pharmaceutical companies continue to cultivate the chinese market to share. The participating foreign enterprises welcomed a series of recent regulatory and policy initiatives in the field of medicine and were willing to continue to expand their investment in china to help build a “healthy china”。
